The health of Valeant Pharmaceuticals International Inc’s Michael Pearson is improving, the company said on Thursday, but CNBC reported that there was debate within the board over whether he was ready to return to work.
Pearson, who joined Valeant as chief executive in 2010, was hospitalized with severe pneumonia in late December.
The company named former Chief Financial Officer Howard Schiller as interim CEO in January.
CNBC, citing a source, said Pearson was ready to return but the board was debating whether he should. (bit.ly/20X0uU8)
(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)
Source: Reuters
The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.
“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.
